SCHEMBL2933857

SCHEMBL2933857

CCCCCCCC/C=C\CCCCCCCCC(O)CCCCCCC/C=C\CCCCCCCC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.62
FFAR4 Q5NUL3 2/20 0.62
FAAH O00519 5/20 0.53
TRPV1 Q8NER1 1/20 0.52
TERT O14746 3/20 0.50
MAPT P10636 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
GPR84 Q9NQS5 2/20 0.50
FABP4 P15090 2/20 0.50
KMT2A Q03164 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALOX15 P16050 1/20 0.50
APEX1 P27695 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070641 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL2826342 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL3274131 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL2621516 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL3185051 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL6008572 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL17744144 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL10081525 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL10085843 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT
SCHEMBL17743910 1.00 FFAR1 (0.62) FFAR1FFAR4FAAHTRPV1TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4321524-B1 LIPID AND COMPOSITION SOGO PHARM (JP) 2025-12-10 EP disclosed
CN-119451677-A Lipid, formulation and use thereof 密歇根大学董事会 2025-02-14 CN disclosed
CN-119212984-A STING agonists, formulations and uses thereof 密歇根大学董事会 2024-12-27 CN disclosed
US-20240148664-A1 LIPID AND COMPOSITION SOGO PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
EP-4321524-A1 LIPID AND COMPOSITION Sogo Pharmaceutical Co., Ltd. (JP) 2024-02-14 EP disclosed
WO-2022215758-A1 LIPID AND COMPOSITION 相互薬工株式会社 2022-10-13 WO disclosed
EP-0909328-B1 BIOLOGICAL PRODUCTION OF ACETIC ACID FROM WASTE GASES EMMAUS FOUNDATION INC (US) 2010-09-29 EP disclosed
WO-2009031890-A2 A CARRIER PARTICLE FOR USE IN BIO-APPLICATIONS UNIVERSITEIT UTRECHT HOLDING B.V. (NL) 2009-03-12 WO disclosed
EP-2030632-A1 A carrier particle for use in bio-applications UMC Utrecht Holding B.V. (NL) 2009-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148664-A1 LIPID AND COMPOSITION PLIN3, PLIN1, FABP1 FFAR1 80/4885FFAR4 193/4885FAAH 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.